Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine in chronic glaucoma
NCT00168350Phase 3Completed
- Sponsor
- Allergan
- Start
- Mar 2000
- Primary completion
- Sep 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of memantine in open-angle glaucoma (OAG) (3 arms), sponsored by Allergan. Primary endpoint: Progression of glaucoma at 48 months. Started Mar 2000; status: completed.
02
Drugs
memantine
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT00168350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168350.